Medexus Pharmaceuticals Inc. (MDP.TO) TSX

2.70

-0.07(-2.53%)

Updated at October 17 03:59PM

Currency In CAD

Medexus Pharmaceuticals Inc.

Address

35 Nixon Road

Bolton, ON L7E 1K1

Canada

Phone

877 633 3987

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

82

First IPO Date

January 09, 2014

Key Executives

NameTitlePayYear Born
Mr. Kenneth d'EntremontChief Executive Officer & Director1.45MN/A
Mr. Brian PetersVice President of Sales & Marketing - United States396,695N/A
Mr. Richard LabelleChief Operating Officer482,291N/A
Mr. Ian C. Wildgoose BrownGeneral Counsel & Corporate Secretary592,667N/A
Mr. Bill PoncySenior Vice President of Commercial Operations - United States613,601N/A
Ms. Tina Byers CFAExecutive of Investor Relations0N/A
Mr. Brendon BuschmanChief Financial Officer0N/A

Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.